PUBLISHER: IMARC | PRODUCT CODE: 1540797
PUBLISHER: IMARC | PRODUCT CODE: 1540797
The global proteomics market size reached US$ 36.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 126.2 Billion by 2032, exhibiting a growth rate (CAGR) of 14.4% during 2024-2032.
Proteomics refers to the study of proteomes, their structure and physiological functions on a large-scale. In 1994, Mark Wilkins first coined the term proteome for the proteins that are translated from genome, to denote the whole set of proteins synthesized within a living organism. It encompasses the modifications and alterations that take place in the existing protein when it is exposed to varying conditions. Proteomics applies various technologies for the quantification and identification of proteins, along with the detection of diagnostic markers, understanding of pathogens in cells and interpretation of protein pathways in different diseases. It also evaluates the rate of protein production and the interaction patterns of proteins due to which it finds extensive applicability in drug discovery and the development of personalized medications.
The growing preference for personalized drugs, along with increasing research and development in drug discovery and biotechnology, is the key factor driving the growth of the market. Proteomic systems reduce the time, cost and resources needed for the chemical synthesis and biological testing of drugs and simplify the process of drug discovery. Furthermore, opportunities related to biomarker identification and mass spectrometry-based proteomics are favoring the market growth further. Additionally, the market is driven by increasing technological penetration in the comprehensive analysis of protein techniques. These techniques include Electrospray Ionization-Liquid Chromatography-Mass Spectrometry (ESI-LC-MS), surface plasma resonance, microarray, protein fractionation systems and X-ray crystallography. These advancements enable a thorough quantitative and qualitative analysis of proteins and identification of cancer therapies and treatments. Other factors, such as favorable government policies for extensive research and development (R&D) are also augmenting the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global proteomics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on analysis type, component type, technology, application and end-user.
Structural Proteomics
Functional Proteomics
Protein Expression Proteomics
Core Proteomics Services
Bioinformatics Software and Related Services
Spectroscopy
Chromatography
Electrophoresis
Protein Microarrays
X-Ray Crystallography
Surface Plasmon Resonance
Others
Protein Expression Profiling
Proteome Mining
Post-translational Modifications
Clinical Diagnostic Laboratories
Research Organizations (Drug Discovery)
Others
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., Waters Corporation, etc.